机构：[1]Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China[2]Department of General Surgery, the First Affiliated Hospital of Soochow University, Suzhou 215006, China[3]Department of Gastrointestinal Surgery, Changshu No. 2 Hospital, Suzhou 215500, China[4]Department of General Surgery, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510000, China[5]Jiangsu Institute Hematology, the First Affiliated Hospital of Soochow University, Suzhou 215006, China[6]Department of Clinical Laboratories, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China[7]Department of General Surgery, the Second Affiliated Hospital of Soochow University, Suzhou 215006, China
Epigenetic changes have been recently recognized as important in human cancers. Enhancer of zeste homologue 2 gene (EZH2) has been shown the overexpression in various human cancers, consistent with a straightforward role of EZH2 as an oncogene, but its function in carcinogenesis is partly contradictory. The role of EZH2 in development of human colorectal cancer (CRC) has not yet been clarified. In the present study, we observed up-regulation of EZH2 expression in tumor tissues from CRC patients. The expression of EZH2 in CRC cell lines is consistent with the trend in cancer tissues using reverse transcription polymerase chain reaction (RT-PCR). We showed that TNM stage and lymph node metastasis in CRC patients are significantly correlated with EZH2 expression levels. EZH2 level of transcription and protein is inhibited by small interfering RNA (siRNA). More importantly, EZH2-siRNA inhibits the proliferation and migration of SW620 cells while promoting their apoptosis, and inducing G0/G1 cell cycle arrest of SW620 cells. Collectively, our results suggest that upregulated EZH2 expression may contribute to the progression of the patients with CRC. A comprehensive study of epigenetic mechanisms and the relevance of EZH2 in CRC is important for fully understanding this disease and as a basis for developing new treatment options in patients with CRC.
基金：
This work was supported by China Postdoctoral Science
Foundation (2013M540374), Shanghai Postdoctoral Scientific
Program of China (13R21415200), Project of Nature Science
Foundation of China (81201905, 81302145), Nature Science
Research Grants in University of Jiangsu Province of China
(12KJB320009), Science and Technology Research Project of in
Science and Technology Bureau of Suzhou City of China
(SYS201220, SYS201330), Post-Graduate Scientific Research
Innovation Project of Education Department of Jiangsu
Province of China (CXZZ12_0842), and sponsored by
Government Overseas Scholarship from Department of
Education of Jiangsu Province
第一作者机构：[1]Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China[2]Department of General Surgery, the First Affiliated Hospital of Soochow University, Suzhou 215006, China
通讯作者：
通讯机构：[1]Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China[2]Department of General Surgery, the First Affiliated Hospital of Soochow University, Suzhou 215006, China
推荐引用方式(GB/T 7714)：
Song-Bing He,Hao Zhou,Jian Zhou,et al.Inhibition of EZH2 expression is associated with the proliferation, apoptosis, and migration of SW620 colorectal cancer cells in vitro[J].EXPERIMENTAL BIOLOGY AND MEDICINE.2015,240(4):458-66.doi:10.1177/1535370214542215.
APA：
Song-Bing He,Hao Zhou,Jian Zhou,Guo-Qiang Zhou,Tuo Han...&De-Chun Li.(2015).Inhibition of EZH2 expression is associated with the proliferation, apoptosis, and migration of SW620 colorectal cancer cells in vitro.EXPERIMENTAL BIOLOGY AND MEDICINE,240,(4)
MLA：
Song-Bing He,et al."Inhibition of EZH2 expression is associated with the proliferation, apoptosis, and migration of SW620 colorectal cancer cells in vitro".EXPERIMENTAL BIOLOGY AND MEDICINE 240..4(2015):458-66
